Risk stratification and treatment goals in pulmonary arterial hypertension
(2024) In The European respiratory journal 64(4).- Abstract
Risk stratification has gained an increasing role in predicting outcomes and guiding the treatment of patients with pulmonary arterial hypertension (PAH). The most predictive prognostic factors are three noninvasive parameters (World Health Organization functional class, 6-min walk distance and natriuretic peptides) that are included in all currently validated risk stratification tools. However, suffering from limitations mainly related to reduced specificity of PAH severity, these variables may not always be adequate in isolation for guiding individualised treatment decisions. Moreover, with effective combination treatment regimens and emerging PAH therapies, markers associated with pulmonary vascular remodelling are expected to become... (More)
Risk stratification has gained an increasing role in predicting outcomes and guiding the treatment of patients with pulmonary arterial hypertension (PAH). The most predictive prognostic factors are three noninvasive parameters (World Health Organization functional class, 6-min walk distance and natriuretic peptides) that are included in all currently validated risk stratification tools. However, suffering from limitations mainly related to reduced specificity of PAH severity, these variables may not always be adequate in isolation for guiding individualised treatment decisions. Moreover, with effective combination treatment regimens and emerging PAH therapies, markers associated with pulmonary vascular remodelling are expected to become of increasing relevance in guiding the treatment of patients with PAH. While reaching a low mortality risk, assessed with a validated risk tool, remains an important treatment goal, preliminary data suggest that invasive haemodynamics and cardiac imaging may add incremental value in guiding treatment decisions.
(Less)
- author
- Dardi, Fabio ; Boucly, Athénaïs ; Benza, Raymond ; Frantz, Robert ; Mercurio, Valentina ; Olschewski, Horst ; Rådegran, Göran LU ; Rubin, Lewis J. and Hoeper, Marius M.
- organization
- publishing date
- 2024-10-01
- type
- Contribution to journal
- publication status
- published
- subject
- in
- The European respiratory journal
- volume
- 64
- issue
- 4
- publisher
- European Respiratory Society
- external identifiers
-
- pmid:39209472
- scopus:85208449813
- ISSN
- 1399-3003
- DOI
- 10.1183/13993003.01323-2024
- language
- English
- LU publication?
- yes
- id
- c024107a-8d0a-4e1d-a7b1-72c208aee996
- date added to LUP
- 2025-01-15 15:16:11
- date last changed
- 2025-03-26 22:52:07
@article{c024107a-8d0a-4e1d-a7b1-72c208aee996, abstract = {{<p>Risk stratification has gained an increasing role in predicting outcomes and guiding the treatment of patients with pulmonary arterial hypertension (PAH). The most predictive prognostic factors are three noninvasive parameters (World Health Organization functional class, 6-min walk distance and natriuretic peptides) that are included in all currently validated risk stratification tools. However, suffering from limitations mainly related to reduced specificity of PAH severity, these variables may not always be adequate in isolation for guiding individualised treatment decisions. Moreover, with effective combination treatment regimens and emerging PAH therapies, markers associated with pulmonary vascular remodelling are expected to become of increasing relevance in guiding the treatment of patients with PAH. While reaching a low mortality risk, assessed with a validated risk tool, remains an important treatment goal, preliminary data suggest that invasive haemodynamics and cardiac imaging may add incremental value in guiding treatment decisions.</p>}}, author = {{Dardi, Fabio and Boucly, Athénaïs and Benza, Raymond and Frantz, Robert and Mercurio, Valentina and Olschewski, Horst and Rådegran, Göran and Rubin, Lewis J. and Hoeper, Marius M.}}, issn = {{1399-3003}}, language = {{eng}}, month = {{10}}, number = {{4}}, publisher = {{European Respiratory Society}}, series = {{The European respiratory journal}}, title = {{Risk stratification and treatment goals in pulmonary arterial hypertension}}, url = {{http://dx.doi.org/10.1183/13993003.01323-2024}}, doi = {{10.1183/13993003.01323-2024}}, volume = {{64}}, year = {{2024}}, }